Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM Announces License Agreement with Amgen

Published: Tuesday, January 15, 2013
Last Updated: Tuesday, January 15, 2013
Bookmark and Share
License agreement for use of DSM's XD® cell culture patents.

DSM Pharmaceutical Products has announced that it has signed a non-exclusive license agreement with Amgen Inc. for access to DSM's proprietary XD® high cell density process patents.

Karen King, President of DSM Biologics, commented “We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing. We believe our proprietary XD® technology will play an important role in the next generation of biopharmaceutical manufacturing."

XD® technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher compared to current standard biomanufacturing processes.

For some products, titer improvements of up to 15 times have been achieved. It is widely applicable for multiple biological products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.

Alexander Wessels, President and CEO of DSM Pharmaceutical Products also commented, "DSM continuously strives to provide its clients with added value through our innovative service and technology offerings."

With typical XD® titer improvement of 8-10X, a 500L bioreactor can provide a DSM licensee with the same amount of drug substance as a 5000L stainless steel bioreactor at an overall lower cost.

DSM's proprietary technologies drive down cost, processing times and capital requirements while increasing flexibility to meet market demand for life saving medications.

XD® has also shown impressive results for biosimilars and innovator drugs with respect to both volume and product quality.

Financial terms were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM Announces Opening of New cGMP Biopharmaceutical Manufacturing Operation
Company announced that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in Brisbane, Australia, in June 2013.
Monday, April 22, 2013
Scientific News
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!